Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Towards Hepatitis C Virus Elimination in Iran: A Blueprint for Comprehensive Strategies Publisher Pubmed



Mousavi S1 ; Alavi M2 ; Delavari A1 ; Poustchi H2 ; Mohammadi Z2 ; Malekzadeh R3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Viral Hepatitis Published:2024


Abstract

The hepatitis C virus (HCV) continues to pose a significant public health challenge in Iran, mirroring a worldwide concern. This situation calls for a cohesive strategy that aligns with the World Health Organization's (WHO) goals for HCV elimination by 2030. Central to this strategy is targeting high-risk groups, notably people who inject drugs and prisoners, with prevention, screening and treatment. The deployment of point-of-care testing and treatments in prisons and harm reduction facilities is vital. The adoption of cost-effective generic direct-acting antivirals represents a major step forward. Furthermore, innovative educational initiatives for healthcare providers and awareness campaigns for the public are critical. Additionally, tackling stigma, ensuring treatment affordability and upholding strict surveillance and data management, coupled with ongoing policy reviews, are vital components. This comprehensive and integrated approach is designed to drive Iran towards eliminating HCV and can serve as a blueprint for other countries with similar challenges. © 2024 John Wiley & Sons Ltd.
Related Docs
View other Related Docs
1. Hepatitis C Virus Infection in Iran: A Review of Current Prevalence and Preventive Strategies From a Developing Country, Journal of Clinical Virology Plus (2024)
2. Single-Pill Sofosbuvir and Daclatasvir for Treating Hepatis C in Patients Co-Infected With Human Immunodeficiency Virus, International Journal of Clinical Practice (2021)
3. Prevalence of Hepatitis B and C Infections and Associated Risk Factors in Pars Cohort Study, Southern Iran, Middle East Journal of Digestive Diseases (2021)
4. Seroepidemiological Investigation of Hepatitis B and C Prevalence and Associated Factors Among People in Custody at Zahedan Central Prison, Archives of Iranian Medicine (2024)
5. Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial, Clinical Infectious Diseases (2020)
6. An Intervention to Increase Hepatitis C Virus Diagnosis and Treatment Uptake Among People in Custody in Iran, International Journal of Drug Policy (2021)
7. Hepatocellular Cancer in Iran, Liver Cancer in the Middle East (2021)
8. A Simple Risk-Based Strategy for Hepatitis C Virus Screening Among Incarcerated People in a Low- to Middle-Income Setting, Harm Reduction Journal (2020)
Experts (# of related papers)
View all Related Experts
Hossein Poustchi (13)
Reza Malekzadeh (11)
Other Related Docs
9. Distribution of Hepatitis C Virus Genotypes and Related Risk Factors Among Iranian Blood Donors: A Penalized Logistic Regression, Jundishapur Journal of Microbiology (2018)
10. Prevalence of and Risk Factors for Hcv Among Incarcerated People at Great Tehran Prison: A Cross-Sectional Study, International Journal of Prisoner Health (2023)
11. Continuum of Hepatitis C Care Cascade in Prison and Following Release in the Direct-Acting Antivirals Era, Harm Reduction Journal (2020)
12. Update on Transmission Modes of Hepatitis C Virus Among Volunteer Iranian Blood Donors: Analysis of a Matched Case-Control Study by Penalized Conditional Logistic Regression, Hepatitis Monthly (2018)
13. Changes in Liver Fibrosis in Patients With Chronic Hepatitis C After Successful Direct-Acting Antiviral Therapy, International Journal of Clinical Practice (2021)
14. An Intervention to Improve Hcv Testing, Linkage to Care, and Treatment Among People Who Use Drugs in Tehran, Iran: The Enhance Study, International Journal of Drug Policy (2019)
15. Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study, The Lancet Gastroenterology and Hepatology (2017)
16. Correlation Between Interleukin-28 Gene Polymorphism With Interleukin-28 Cytokine Levels and Viral Genotypes Among Hcv Patients in Yazd, Iran, BMC Research Notes (2019)
17. Efficacy of Locally Manufactured Sofosbuvir and Daclatasvir (Sovodak) in Combination With Ribavirin in Treating Patients With Chronic Hepatitis C and Cirrhosis in Iran - Preliminary Report, Govaresh (2016)
18. The Present and Future Disease Burden of Hepatitis C Virus Infections With Today's Treatment Paradigm - Volume 3, Journal of Viral Hepatitis (2015)
19. Prevalence of Hav Ab, Hev (Igg), Hsv2 Igg, and Syphilis Among Sheltered Homeless Adults in Tehran, 2012, International Journal of Health Policy and Management (2018)
20. High Level of Vaccination and Protection Against Hepatitis B With Low Rate of Hcv Infection Markers Among Hospital Health Care Personnel in North of Iran: A Cross-Sectional Study, BMC Public Health (2020)
21. Seroprevalence of Hepatitis B Virus and Hepatitis C Virus Infections Among People With Severe Mental Illness in Tehran, Iran, Hepatitis Monthly (2022)
22. The Impact of Sofosbuvir/Daclatasvir or Ribavirin in Patients With Severe Covid-19, Journal of Antimicrobial Chemotherapy (2020)
23. Hepatitis B Virus Infection Among People Who Use Drugs in Iran: A Systematic Review, Meta-Analysis, and Trend Analysis, Harm Reduction Journal (2020)
24. An Overview of the Action Plans of the Islamic Republic of Iran Toward Elimination of Viral Hepatitis B and C, Journal of Mazandaran University of Medical Sciences (2023)
25. Prevalence of Hepatitis C Infection in Iranian Hemodialysis Patients: An Updated Systematic Review and Meta-Analysis, Journal of Research in Medical Sciences (2017)
26. A Quick and Sensitive Lc-Ms/Ms Method for Simultaneous Quantification of Sofosbuvir Metabolite (Gs-331007) in Human Plasma: Application to Hepatitis C Infected Patients With End-Stage Renal Disease, Middle East Journal of Digestive Diseases (2024)
27. The Efficacy of 12Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients With Cirrhosis, Genotypes 1 and 3, Hepatitis Monthly (2017)
28. Performance of a Rapid Diagnostic Test for Screening of Hepatitis C in a Real-Life Prison Setting, Journal of Clinical Virology (2019)
29. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis, Hepatitis Monthly (2017)